<DOC>
	<DOCNO>NCT00450853</DOCNO>
	<brief_summary>Objective : evaluate bioavailability subcutaneous granisetron.Patients receive platinum-based chemotherapy randomize receive granisetron 3 mg either subcutaneously intravenously crossover manner two cycle . Blood urine sample collect cycle .</brief_summary>
	<brief_title>Randomized Crossover Pharmacokinetic Evaluation Subcutaneous Versus Intravenous Granisetron Cancer Patients</brief_title>
	<detailed_description>5-HT3 antagonist one mainstays antiemetic treatment administer either intravenously orally . Nevertheless sometimes neither administration route feasible , patient unable admit oral intake manage outpatient setting . Our objective evaluate bioavailability subcutaneous granisetron.Patients receive platinum-based chemotherapy randomize receive granisetron 3 mg either subcutaneously intravenously crossover manner two cycle . Blood urine sample collect cycle . Pharmacokinetics SC IV granisetron prospectively compare .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Cancer patient receive platinumbased chemotherapy adequate bone marrow , hepatic renal function , respectively define : platelet &gt; 100000/mm3 absolute neutrophil count &gt; 1500/mm3 ; bilirubin , AST ALT &lt; 2 time x upper limit normality ; creatinine &lt; 1.5 mg/dl . ECOG performance status &lt; 2 body mass index 2028 kg/m2 . Pregnancy Serious concomitant disease , invesgatorÂ´s criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>emesis</keyword>
	<keyword>granisetron</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>subcutaneous .</keyword>
</DOC>